Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Sonoma Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Sonoma Pharmaceuticals, Inc.

SNOA

Sonoma Pharmaceuticals, Inc.

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals specializes in developing and manufacturing stabilized hypochlorous acid (HOCl) products for healthcare and disinfection. Its core segments include wound care, dermatology, eye, oral, nasal, podiatry, animal health, and surface disinfectants. The company markets globally through direct sales and partnerships, emphasizing safe, effective, and cost-efficient solutions backed by extensive regulatory approvals and proprietary technology.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Sonoma Pharmaceuticals, Inc.

1
1
Sonoma Pharmaceuticals, Inc. Sonoma Pharmaceuticals Reports 22% Revenue Growth to $4.35 Million for Quarter Ended December 31, 2025

Via official filing (AI summary) | 4 months ago | 0 comments

2
1
Sonoma Pharmaceuticals, Inc. Sonoma Pharmaceuticals Reports 57% Revenue Increase in Q2 FY 2026

Via official filing (AI summary) | 7 months ago | 0 comments

3
1
Sonoma Pharmaceuticals, Inc. Sonoma Pharmaceuticals Reports 18% Revenue Increase to $4.015 Million for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

4
1
Sonoma Pharmaceuticals, Inc. Sonoma Pharmaceuticals Reports 31% Revenue Growth, Improved Financials in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments